http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106966941-B

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-54
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D205-08
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D205-08
filingDate 2017-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2019-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2019-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-106966941-B
titleOfInvention The method that overcritical compression Anti-solvent Precipitation prepares ezetimibe ultrafine dust
abstract The present invention relates to the methods that the overcritical compression Anti-solvent Precipitation of application prepares ezetimibe ultrafine dust, comprising: ezetimibe bulk pharmaceutical chemicals are dissolved in organic solvent, prepare ezetimibe solution;By CO 2 It is passed through crystallization kettle with certain volume flow, adjusts the temperature and pressure in crystallization kettle, and maintain stable state;The ezetimibe solution prepared before is passed through crystallization kettle with preset sample introduction flow velocity;After sample introduction, it is continually fed into CO 2 , whole process maintain crystallization kettle in temperature and pressure it is constant, release after a period of time;Pressure in kettle to be crystallized be down to it is equal with atmospheric pressure after, open crystallization kettle collect ezetimibe ultrafine dust, carry out a series of phenetic analysis later.Compared with untreated bulk pharmaceutical chemicals, ezetimibe ultra-fine grain particle size produced by the present invention is reduced by about 80% and crystal form does not change.On technological layer, the present invention has operating condition mild, green high-efficient, almost the advantages that no solvent residue.
priorityDate 2017-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID150311
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID4530
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419485881
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534626
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441478
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID4530

Total number of triples: 19.